Selected research
Market Structure
Global Alzheimer’s Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Alzheimer’s Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Alzheimer’s Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Alzheimer’s Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Alzheimer’s Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Alzheimer’s Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Alzheimer’s Drugs include Eisai Co Ltd., Johnson & Johnson, Daiichi Sankyo Company Limited, Ono Pharmaceutical and H Lundbeck A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Alzheimer’s Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Alzheimer’s Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Alzheimer’s Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alzheimer’s Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Alzheimer’s Drugs Segment by Company
Eisai Co Ltd.
Johnson & Johnson
Daiichi Sankyo Company Limited
Ono Pharmaceutical
H Lundbeck A/S
Alzheimer’s Drugs Segment by Type
Memantine
CombinedDrug
Cholinergic
Alzheimer’s Drugs Segment by Application
Online Sales
Hospital Pharmacy
Retail Pharmacy
Alzheimer’s Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer’s Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alzheimer’s Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer’s Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Alzheimer’s Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alzheimer’s Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Alzheimer’s Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Alzheimer’s Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Memantine
- CombinedDrug
- Cholinergic
Applications
- Online Sales
- Hospital Pharmacy
- Retail Pharmacy
Companies covered
- Eisai Co Ltd.
- Johnson & Johnson
- Daiichi Sankyo Company Limited
- Ono Pharmaceutical
- H Lundbeck A/S
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Alzheimer’s Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Alzheimer’s Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Alzheimer’s Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Alzheimer’s Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Alzheimer’s Drugs Market Dynamics
- 2.1 Alzheimer’s Drugs Industry Trends
- 2.2 Alzheimer’s Drugs Industry Drivers
- 2.3 Alzheimer’s Drugs Industry Opportunities and Challenges
- 2.4 Alzheimer’s Drugs Industry Restraints
3 Alzheimer’s Drugs Market by Manufacturers
- 3.1 Global Alzheimer’s Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Alzheimer’s Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Alzheimer’s Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Alzheimer’s Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Alzheimer’s Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Alzheimer’s Drugs Manufacturers, Product Type & Application
- 3.7 Global Alzheimer’s Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Alzheimer’s Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Alzheimer’s Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Alzheimer’s Drugs Tier 1, Tier 2, and Tier 3
4 Alzheimer’s Drugs Market by Type
- 4.1 Alzheimer’s Drugs Type Introduction
- 4.1.1 Memantine
- 4.1.2 CombinedDrug
- 4.1.3 Cholinergic
- 4.2 Global Alzheimer’s Drugs Sales by Type
- 4.2.1 Global Alzheimer’s Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Alzheimer’s Drugs Sales by Type (2021-2032)
- 4.2.3 Global Alzheimer’s Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Alzheimer’s Drugs Revenue by Type
- 4.3.1 Global Alzheimer’s Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Alzheimer’s Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Alzheimer’s Drugs Revenue Market Share by Type (2021-2032)
5 Alzheimer’s Drugs Market by Application
- 5.1 Alzheimer’s Drugs Application Introduction
- 5.1.1 Online Sales
- 5.1.2 Hospital Pharmacy
- 5.1.3 Retail Pharmacy
- 5.2 Global Alzheimer’s Drugs Sales by Application
- 5.2.1 Global Alzheimer’s Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Alzheimer’s Drugs Sales by Application (2021-2032)
- 5.2.3 Global Alzheimer’s Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Alzheimer’s Drugs Revenue by Application
- 5.3.1 Global Alzheimer’s Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Alzheimer’s Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Alzheimer’s Drugs Revenue Market Share by Application (2021-2032)
6 Global Alzheimer’s Drugs Sales by Region
- 6.1 Global Alzheimer’s Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Alzheimer’s Drugs Sales by Region (2021-2032)
- 6.2.1 Global Alzheimer’s Drugs Sales by Region (2021-2026)
- 6.2.2 Global Alzheimer’s Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Alzheimer’s Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Alzheimer’s Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Alzheimer’s Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Alzheimer’s Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Alzheimer’s Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Alzheimer’s Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Alzheimer’s Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Alzheimer’s Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Alzheimer’s Drugs Revenue by Region
- 7.1 Global Alzheimer’s Drugs Revenue by Region
- 7.1.1 Global Alzheimer’s Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Alzheimer’s Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Alzheimer’s Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Alzheimer’s Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Alzheimer’s Drugs Revenue (2021-2032)
- 7.2.2 North America Alzheimer’s Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Alzheimer’s Drugs Revenue (2021-2032)
- 7.3.2 Europe Alzheimer’s Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Alzheimer’s Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Alzheimer’s Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Alzheimer’s Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Alzheimer’s Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Eisai Co Ltd.
- 8.1.1 Eisai Co Ltd. Company Information
- 8.1.2 Eisai Co Ltd. Business Overview
- 8.1.3 Eisai Co Ltd. Alzheimer’s Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Eisai Co Ltd. Alzheimer’s Drugs Product Portfolio
- 8.1.5 Eisai Co Ltd. Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Alzheimer’s Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Alzheimer’s Drugs Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Daiichi Sankyo Company Limited
- 8.3.1 Daiichi Sankyo Company Limited Company Information
- 8.3.2 Daiichi Sankyo Company Limited Business Overview
- 8.3.3 Daiichi Sankyo Company Limited Alzheimer’s Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Daiichi Sankyo Company Limited Alzheimer’s Drugs Product Portfolio
- 8.3.5 Daiichi Sankyo Company Limited Recent Developments
- 8.4 Ono Pharmaceutical
- 8.4.1 Ono Pharmaceutical Company Information
- 8.4.2 Ono Pharmaceutical Business Overview
- 8.4.3 Ono Pharmaceutical Alzheimer’s Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Ono Pharmaceutical Alzheimer’s Drugs Product Portfolio
- 8.4.5 Ono Pharmaceutical Recent Developments
- 8.5 H Lundbeck A/S
- 8.5.1 H Lundbeck A/S Company Information
- 8.5.2 H Lundbeck A/S Business Overview
- 8.5.3 H Lundbeck A/S Alzheimer’s Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 H Lundbeck A/S Alzheimer’s Drugs Product Portfolio
- 8.5.5 H Lundbeck A/S Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Alzheimer’s Drugs Value Chain Analysis
- 9.1.1 Alzheimer’s Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Alzheimer’s Drugs Production Mode & Process
- 9.2 Alzheimer’s Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Alzheimer’s Drugs Distributors
- 9.2.3 Alzheimer’s Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst